News

Lebrikizumab is a novel and humanized monoclonal antibody designed to specifically block the action of IL-13, a cytokine that is a central pathogenic mediator in atopic dermatitis. Roche

The acquisition, expands the Group’s presence within the US healthcare market and increases US sales by more than double, bringing together two highly complementary technology and product platforms

The Neurological Clinical Research Institute (NCRI) at the Massachusetts General Hospital (MGH) and the Northeast ALS Consortium (NEALS) will oversee the trial, and 25 NEALS member medical centers

ECD is a rare, serious blood disease characterized by the abnormal multiplication of certain white blood cells called histiocytes. Zelboraf was also granted Breakthrough Therapy Designation (BTD) by

This is in addition to the existing MIA (IMP) licence for Investigational Medicinal Products (IMPs) manufacture, which the Group has held for over 10 years. Including significant know-how

The trial dubbed as STAR 1 was held in 188 adult epilepsy patients with focal seizures across 14 sites in Australia and New Zealand. When compared to placebo,

MAVYRET is an 8-week, pan-genotypic treatment for patients without cirrhosis and who are new to treatment. Up to 95 percent of HCV patients in the U.S. may be

According to the agreement, HitGen will use its advanced technology platform, based on DNA-encoded library design, synthesis and screening to discover novel leads which will be licensed exclusively

According to Lilly, the primary endpoint of the phase 3 SPARTAN trial was comparison of the percentage of patients in the lasmiditan 200mg and placebo groups who were